169 related articles for article (PubMed ID: 36300810)
21. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
22. Dendritic Nanomedicine with Boronate Bonds for Augmented Chemo-Immunotherapy via Synergistic Modulation of Tumor Immune Microenvironment.
Li Y; Wu Y; Fang Z; Zhang Y; Ding H; Ren L; Zhang L; Gong Q; Gu Z; Luo K
Adv Mater; 2024 Jan; 36(2):e2307263. PubMed ID: 37743633
[TBL] [Abstract][Full Text] [Related]
23. A complex micellar system co-delivering curcumin with doxorubicin against cardiotoxicity and tumor growth.
Zhang D; Xu Q; Wang N; Yang Y; Liu J; Yu G; Yang X; Xu H; Wang H
Int J Nanomedicine; 2018; 13():4549-4561. PubMed ID: 30127606
[TBL] [Abstract][Full Text] [Related]
24. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
[TBL] [Abstract][Full Text] [Related]
25. Dendritic polymer-functionalized nanomedicine potentiates immunotherapy via lethal energy crisis-induced PD-L1 degradation.
Li X; Duan Z; Li Z; Gu L; Li Y; Gong Q; Gu Z; Luo K
Biomaterials; 2023 Nov; 302():122294. PubMed ID: 37657175
[TBL] [Abstract][Full Text] [Related]
26. Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy.
Zhu L; Li J; Guo Z; Kwok HF; Zhao Q
J Nanobiotechnology; 2022 Dec; 20(1):521. PubMed ID: 36496381
[TBL] [Abstract][Full Text] [Related]
27. A Redox-Responsive Nanovaccine Combined with A2A Receptor Antagonist for Cancer Immunotherapy.
Yan P; Luo Y; Li X; Li Y; Wang Y; Wu J; Zhou S
Adv Healthc Mater; 2021 Nov; 10(21):e2101222. PubMed ID: 34494380
[TBL] [Abstract][Full Text] [Related]
28. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma.
Xu J; Zheng Q; Cheng X; Hu S; Zhang C; Zhou X; Sun P; Wang W; Su Z; Zou T; Song Z; Xia Y; Yi X; Gao Y
J Nanobiotechnology; 2021 Oct; 19(1):355. PubMed ID: 34717654
[TBL] [Abstract][Full Text] [Related]
29. Codelivered Chemotherapeutic Doxorubicin
Lan Y; Liang Q; Sun Y; Cao A; Liu L; Yu S; Zhou L; Liu J; Zhu R; Liu Y
ACS Appl Mater Interfaces; 2020 Jul; 12(28):31904-31921. PubMed ID: 32551517
[TBL] [Abstract][Full Text] [Related]
30. Multifunctional Liposomes Remodeling Tumor Immune Microenvironment for Tumor Chemoimmunotherapy.
Li X; Luo Y; Huang Z; Wang Y; Wu J; Zhou S
Small Methods; 2023 May; 7(5):e2201327. PubMed ID: 37075716
[TBL] [Abstract][Full Text] [Related]
31. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
32. Zwitterionic Injectable Hydrogel-Combined Chemo- and Immunotherapy Medicated by Monomolecular Micelles to Effectively Prevent the Recurrence of Tumor Post Operation.
Wang R; Hu Q; Huang S; Fang Y; Kong X; Kaur P; Zhang J; Wang Y; Liu D; Wu H; Li Y; Ji J; Yang X; Ye L; Zhai G
ACS Appl Mater Interfaces; 2024 Jan; 16(3):4071-4088. PubMed ID: 38194589
[TBL] [Abstract][Full Text] [Related]
33. TME-Responsive Polyprodrug Micelles for Multistage Delivery of Doxorubicin with Improved Cancer Therapeutic Efficacy in Rodents.
Zhang S; Zhu P; He J; Dong S; Li P; Zhang CY; Ma T
Adv Healthc Mater; 2020 Sep; 9(18):e2000387. PubMed ID: 32815646
[TBL] [Abstract][Full Text] [Related]
34. All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy.
Song S; Shim MK; Yang S; Lee J; Yun WS; Cho H; Moon Y; Min JY; Han EH; Yoon HY; Kim K
Bioact Mater; 2023 Oct; 28():358-375. PubMed ID: 37334068
[TBL] [Abstract][Full Text] [Related]
35. Chemoimmunological Cascade Cancer Therapy Using Fluorine Assembly Nanomedicine.
Zhang Q; Wu P; Wu J; Shou H; Ming X; Wang S; Wang B
ACS Nano; 2023 Apr; 17(8):7498-7510. PubMed ID: 37011376
[TBL] [Abstract][Full Text] [Related]
36. Engineered Stable Bioactive Per Se Amphiphilic Phosphorus Dendron Nanomicelles as a Highly Efficient Drug Delivery System To Take Down Breast Cancer In Vivo.
Chen L; Cao L; Zhan M; Li J; Wang D; Laurent R; Mignani S; Caminade AM; Majoral JP; Shi X
Biomacromolecules; 2022 Jul; 23(7):2827-2837. PubMed ID: 35694854
[TBL] [Abstract][Full Text] [Related]
37. Cucurbitacin IIa promotes the immunogenic cell death‑inducing effect of doxorubicin and modulates immune microenvironment in liver cancer.
Li S; Wang S; Zhang A; Luo L; Song J; Wei G; Fang Z
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38391053
[TBL] [Abstract][Full Text] [Related]
38. Fibronectin-Coated Metal-Phenolic Networks for Cooperative Tumor Chemo-/Chemodynamic/Immune Therapy via Enhanced Ferroptosis-Mediated Immunogenic Cell Death.
Xu Y; Guo Y; Zhang C; Zhan M; Jia L; Song S; Jiang C; Shen M; Shi X
ACS Nano; 2022 Jan; 16(1):984-996. PubMed ID: 35023715
[TBL] [Abstract][Full Text] [Related]
39. Co-Delivery of Paclitaxel and Doxorubicin by pH-Responsive Prodrug Micelles for Cancer Therapy.
Jiang Y; Zhou Y; Zhang CY; Fang T
Int J Nanomedicine; 2020; 15():3319-3331. PubMed ID: 32494132
[TBL] [Abstract][Full Text] [Related]
40. Cooperative Self-Assembled Nanoparticle Induces Sequential Immunogenic Cell Death and Toll-Like Receptor Activation for Synergistic Chemo-immunotherapy.
Wang Y; Wang Z; Chen B; Yin Q; Pan M; Xia H; Zhang B; Yan Y; Jiang Z; Zhang Q; Wang Y
Nano Lett; 2021 May; 21(10):4371-4380. PubMed ID: 33984236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
